D J Fisher1, W J Dreyer, C Tate
1Lillie Frank Abercrombie Section of Pediatric Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
This study investigated whether natural opioid substances contribute to heart function problems caused by high acid levels in the blood. Researchers found that blocking these opioids did not improve heart performance during acidemia, suggesting they are not the primary cause of the observed dysfunction.
Area of Science:
Background:
No prior work had resolved if internal opioid signaling pathways contribute to heart failure during severe metabolic acidemia. It was already known that hydrochloric acid infusions trigger significant declines in cardiac performance. That uncertainty drove researchers to examine if opioid receptors play a role in this pathology. Prior research has shown that acid-induced drops in blood pH correlate with reduced pumping capacity. This gap motivated the current investigation into whether opioid blockade could reverse such cardiac deficits. Scientists previously established that these chemical changes lead to decreased stroke volume and altered pressure dynamics. Understanding these mechanisms remains a challenge for neonatal cardiovascular care. This study provides a necessary evaluation of opioid involvement in acid-related myocardial impairment.
Purpose Of The Study:
The aim of this investigation was to determine if endogenous opioid activity mediates the cardiac dysfunction associated with metabolic acidemia. Researchers sought to test the hypothesis that opioid receptors contribute to the observed contractile and pump failures. This study addressed the uncertainty regarding whether opioid blockade could alleviate heart performance issues during severe acid-base disturbances. The motivation stemmed from previous evidence showing that hydrochloric acid infusions lead to significant hemodynamic impairment in neonatal models. By inhibiting these pathways, the team intended to isolate the specific influence of opioids on myocardial depression. They aimed to compare these effects against established restorative treatments like sodium bicarbonate. This research was designed to clarify the underlying pathophysiology of acid-induced cardiovascular decline. The study provides a critical assessment of whether opioid signaling is a viable target for therapeutic intervention.
The researchers propose that endogenous opioids do not mediate the heart dysfunction caused by metabolic acidemia. While naloxone blockade slightly improved the maximal first derivative of left ventricular pressure, it failed to significantly alter cardiac output, stroke volume, or systemic vascular resistance compared to untreated acidemic states.
The study utilized naloxone, a potent opioid receptor antagonist, to inhibit endogenous opioid activity. This agent was confirmed to effectively block morphine sulfate-induced heart dysfunction before being applied to the acidemia model in the newborn lamb subjects.
Instrumentation included pacing wires on the right atrial appendage, a micromanometer pressure transducer within the left ventricle, and a thermistor in the abdominal aorta. These tools were necessary to precisely measure hemodynamic variables like cardiac output and pressure derivatives in the neonatal lambs.
Main Methods:
The team performed a controlled physiological study using eighteen newborn lambs as the primary experimental model. Review approach involved surgical catheterization and instrumentation three days prior to the formal data collection period. Investigators monitored hemodynamic performance using specialized pressure transducers and thermistors placed within the heart and aorta. Metabolic acidemia was induced through the controlled intravenous infusion of hydrochloric acid into the inferior vena cava. The researchers administered a bolus of naloxone to inhibit opioid receptors during the acidemic state. They validated the efficacy of this blockade by testing its ability to prevent morphine-induced cardiac depression. The study design contrasted these results against historical data regarding sodium bicarbonate therapy. This systematic approach allowed for the precise evaluation of opioid-mediated cardiovascular responses.
Main Results:
Key findings from the literature indicate that reducing arterial pH to 6.97 caused a 45% reduction in cardiac output. This decline was primarily driven by a 50% decrease in stroke volume across the subjects. The researchers observed a 35% reduction in the maximal first derivative of left ventricular pressure, indicating impaired contractility. Systemic vascular resistance increased by 63%, which reflected significant changes in afterload during the acidemic challenge. Left ventricular end diastolic pressure also rose during the period of metabolic acidemia. Opioid inhibition via naloxone produced only a minor, consistent increase in the maximal first derivative of left ventricular pressure. This change did not correlate with any significant improvement in cardiac output or stroke volume. The data confirm that opioid blockade failed to reverse the hemodynamic deficits induced by the acid infusion.
Conclusions:
The authors propose that internal opioid activity does not drive the heart dysfunction observed during metabolic acidemia. Synthesis and implications suggest that blocking these receptors fails to restore cardiac output or stroke volume. These findings indicate that other physiological pathways must account for the observed reduction in contractility. The researchers contrast these results with bicarbonate therapy, which successfully reverses acid-induced cardiac changes. Their data show that opioid inhibition causes only minor improvements in pressure derivatives without systemic benefits. This study clarifies that endogenous opioids are not the primary mediators of acid-related myocardial depression. The evidence supports the conclusion that opioid blockade is ineffective for treating this specific condition. Future investigations should focus on alternative mechanisms to explain the observed cardiovascular decline.
The researchers used hydrochloric acid infusions to induce metabolic acidemia, reducing arterial pH from 7.41 to 6.97. This model allowed them to quantify the resulting 45% reduction in cardiac output and 50% decrease in stroke volume for comparison against opioid-blocked states.
The team measured the maximal first derivative of left ventricular pressure to estimate contractility and systemic vascular resistance to assess afterload. These metrics allowed the researchers to determine that acidemia significantly impaired both parameters, whereas opioid inhibition provided only negligible changes to these values.
The authors state that their findings contrast with bicarbonate therapy, which restores normal arterial pH and cardiac function. They conclude that since opioid inhibition does not mimic the restorative effects of bicarbonate, opioids are not the mediators of the observed cardiovascular impairment.